{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:47:34Z","timestamp":1782384454375,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00429-8","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:47:09Z","timestamp":1774529229000},"page":"671-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Binod","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Y.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenze","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Le Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-2844","authenticated-orcid":false,"given":"Sarah","family":"Lucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camryn","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Giegerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaLyna","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niodita","family":"Gupta-Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"2","key":"429_CR1","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322\u201347.","journal-title":"Curr Oncol"},{"key":"429_CR2","unstructured":"American Cancer Society. Cancer facts & figures 2025. 2025. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2025-cancer-facts-figures.html. Accessed 16 Aug 2025."},{"key":"429_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19547","volume":"43","author":"J Kenmoe","year":"2025","unstructured":"Kenmoe J, Rabadi A, Kunadi A. Beyond the numbers: dissecting racial and gender disparities in myeloma mortality. J Clin Oncol. 2025;43:e19547.","journal-title":"J Clin Oncol"},{"issue":"9","key":"429_CR4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"issue":"12","key":"429_CR5","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1038\/s41375-020-0857-2","volume":"34","author":"J Mikhael","year":"2020","unstructured":"Mikhael J, Richter J, Vij R, et al. A dose-finding phase\u00a02 study of single agent isatuximab (anti-CD38 mAb) in relapsed\/refractory multiple myeloma. Leukemia. 2020;34(12):3298\u2013309.","journal-title":"Leukemia"},{"key":"429_CR6","unstructured":"Tecvayli (teclistamab-cqyv) [package insert]. Horsham, PA: Johnson & Johnson; 2026. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/TECVAYLI-pi.pdf. Accessed 16 Aug 2025."},{"issue":"6","key":"429_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"429_CR8","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"A Garfall","year":"2024","unstructured":"Garfall A, Nooka A, van de Donk N, et al. Long-term follow-up from the phase\u00a01\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024; 42(16 Suppl.):7540.","journal-title":"J Clin Oncol"},{"key":"429_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200354","volume":"144","author":"TG Martin","year":"2024","unstructured":"Martin TG, Mateos MV, van de Donk N, et al. Pooled efficacy and safety of teclistamab in 217 patients with triple-class exposed relapsed\/refractory multiple myeloma from 3 registrational clinical studies. Blood. 2024;144:3331.","journal-title":"Blood"},{"key":"429_CR10","first-page":"154","volume":"15","author":"C Wagner","year":"2025","unstructured":"Wagner C, Steinback M, Verducci D, Kowalski A. BCMA-directed bispecific antibodies for multiple myeloma: practical approaches to patient management. J Hematol Oncol Pharma. 2025;15:154\u201366.","journal-title":"J Hematol Oncol Pharma"},{"issue":"10301","key":"429_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen\u2009\u00d7\u2009CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase\u00a01 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"issue":"6","key":"429_CR12","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0186","volume":"12","author":"A Krishnan","year":"2023","unstructured":"Krishnan A, Nooka AK, Chari A, et al. Teclistamab versus real-world physician\u2019s choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma. J Comp Eff Res. 2023;12(6):e220186.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"429_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","volume":"23","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, Chari A, Usmani SZ, et al. Comparative efficacy of teclistamab versus physician\u2019s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(5):385\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"429_CR14","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective locoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412\u201325.","journal-title":"Adv Ther"},{"key":"429_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0354","author":"BM Razzo","year":"2025","unstructured":"Razzo BM, Midha S, Portuguese AJ, et al. Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US myeloma immunotherapy consortium. Blood Cancer Discov. 2025;6(6):61-71.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"429_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan CR, Asoori S, Huang CY, et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group study. Blood Cancer J. 2025;15(1):53.","journal-title":"Blood Cancer J"},{"issue":"3","key":"429_CR17","doi-asserted-by":"publisher","first-page":"308 e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024;30(3):308 e1-e13.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"429_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14(1):35.","journal-title":"Blood Cancer J"},{"issue":"2","key":"429_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38(2):365\u201371.","journal-title":"Leukemia"},{"issue":"7","key":"429_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071235","volume":"17","author":"B Derman","year":"2025","unstructured":"Derman B, Tan C, Steinfield I, et al. Real-world evidence evaluating teclistamab in patients with relapsed\/refractory multiple myeloma: a systematic literature review. Cancers (Basel). 2025;17(7):1235.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"429_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36741","volume":"4","author":"BA Feinberg","year":"2021","unstructured":"Feinberg BA, Zettler ME, Klink AJ, Lee CH, Gajra A, Kish JK. Comparison of solid tumor treatment response observed in clinical practice with response reported in clinical trials. JAMA Netw Open. 2021;4(2):e2036741.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"429_CR22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"429_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2024-209008","volume":"144","author":"A Afrough","year":"2024","unstructured":"Afrough A, Khan A, Chinaeke E, et al. Real-world characteristics and outcomes in patients with multiple myeloma receiving teclistamab step-up doses in academic vs. community settings. Blood. 2024;144(Suppl. 1):933.","journal-title":"Blood"},{"key":"429_CR24","doi-asserted-by":"crossref","unstructured":"Rees JH. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors I, editors. The EBMT\/EHA CAR-T Cell Handbook. Cham (CH); 2022. p. 141\u20135.","DOI":"10.1007\/978-3-030-94353-0_27"},{"issue":"1","key":"429_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"429_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116.","journal-title":"Blood Cancer J"},{"issue":"5","key":"429_CR27","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, et al. International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205-16.","journal-title":"Lancet Oncol"},{"key":"429_CR28","unstructured":"Kumar SK, Callander NS, Adekola K, et al. NCCN clinical practice guidelines in Oncology Multiple Myeloma Version 1.2025 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Referenced with permission from the\u00a0NCCN\u00a0Clinical Practice Guidelines in Oncology (NCCN\u00a0Guidelines\u00ae) for\u00a0Multiple Myeloma V.2.2026. \u00a9 National Comprehensive Cancer Network, Inc.\u00a02026. All rights reserved. To view the most recent and complete version of the guideline, go online to\u00a0NCCN.org. Accessed\u00a018 Nov 2025."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00429-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:53:45Z","timestamp":1782381225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00429-8","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Binod Dhakal received research funding from Arcellx, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Gracell, Janssen, Menarini and Sanofi; received honoraria from BMS, Janssen and Karyopharm; served on advisory boards for Arcellx, BMS, Genentech, GSK, Janssen, Karyopharm, Kite, Menarini, Pfizer and Sanofi. Moshe Y Levy is a speaker\/consultant for Johnson & Johnson. Gilbert Ko, Jinghua He, Nina Kim, Wenze Tang, Tonya LeBlanc, Jessica Fowler, Niodita Gupta-Werner, and Shuchita Kaila are employees of Johnson & Johnson and may hold stock options and\/or shares in Johnson & Johnson. Sarah Lucht, Camryn Craig, Bruce Feinberg, Madison Brown, Emily Bland, Sarah Giegerich, and JaLyna Laney are employees of Cardinal Health, which received fees from Johnson & Johnson for the conduct of this research. Peter Voorhees received honoraria for advisory boards from AbbVie Inc, Ascentage Pharma, AstraZeneca, Bristol-Myers Squibb, GSK, Johnson & Johnson, Kite, Pfizer, Regeneron and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All physicians in OPEN are able to participate in research overseen by a central institutional review board (IRB). This study was exempt from review by an IRB because the database is compliant with the Health Insurance Portability and Accountability Act (HIPAA), does not involve interaction or interview with any patients, and does not include any individually identifiable data. As such this study is not research involving human patients, as defined in 45 CFR 46.102(f)(2). This study used existing fully de-identified data and the investigators cannot be identified, directly or through identifiers linked to patients, and therefore is exempt from all 45 CFR part 46 requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}